United States. Food and Drug Administration

Pharmaceutical industry

CoTherix Initiates Phase II Trial for Ventavis to Treat Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis

CoTherix, Inc., has initiated a phase II trial for its marketed product, Ventavis (iloprost) Inhalation Solution, aiming to expand its indication to include pulmonary hypertension (PH) associated with idiopathic pulmonary fibrosis (IPF). The double-blind, placebo-controlled trial, known as the ACTIVE trial, will enroll approximately 50 patients at 15 sites in